SCA
AVNR

SAC Capital Advisors’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

SAC Capital Advisors’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-25,798
Closed -$95K – 1584
2014
Q1 		$95K Buy
25,798
+3,737
+17% +$14.2K ﹤0.01% 1676
2013
Q4 		$74K Buy
22,061
+7,561
+52% +$31.2K ﹤0.01% 1732
2013
Q3 		$61K Buy
+14,500
New +$68.7K ﹤0.01% 1711

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

SAC Capital Advisors's AVNR Position: Q2 2014 in Review

SAC Capital Advisors sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q2 2014, closing a stake of 25,798 shares — an estimated $95K sold.

SAC Capital Advisors first reported a position in AVNR in Q3 2013 and held it in 3 quarters. The position peaked at $95K in Q1 2014. 115 funds tracked by Wall St. Rank hold AVNR as of Q2 2014.

  • SAC Capital Advisors reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 25,798 AVANIR PHARMACEUTICALS, INC CL A shares in Q2 2014, an estimated $95K.
  • SAC Capital Advisors first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q3 2013 and held it in 3 quarters.
  • SAC Capital Advisors's AVANIR PHARMACEUTICALS, INC CL A position peaked at $95K in Q1 2014.
  • 115 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.